Literature DB >> 24925586

Treatment of severe and/or refractory ANCA-associated vasculitis.

Loïc Guillevin1.   

Abstract

Most patients presenting with systemic necrotizing vasculitides improve when they are adequately treated. The presence of life-threatening manifestations or visceral involvement modifying organ function characterizes severe vasculitis, confirmed by disease-severity scores. Sequelae cannot always be predicted and prevented but organ involvement present at disease onset requires rapid therapeutic intervention. Some patients present a persistent active disease, which does not respond to treatments and deserve other drugs or combination of drugs. The therapeutic options for severe and/or relapsing and refractory diseases are described.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24925586     DOI: 10.1007/s11926-014-0430-y

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  42 in total

1.  Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients.

Authors:  Pascal Cohen; Christian Pagnoux; Alfred Mahr; Jean-Pierre Arène; Luc Mouthon; Véronique Le Guern; Marie-Hélène André; Martine Gayraud; David Jayne; Daniel Blöckmans; Jean-François Cordier; Loïc Guillevin
Journal:  Arthritis Rheum       Date:  2007-05-15

2.  Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients.

Authors:  L Josselin; A Mahr; P Cohen; C Pagnoux; G Guaydier-Souquières; G Hayem; C Job-Deslandre; F Liferman; J Pourrat; L Guillevin
Journal:  Ann Rheum Dis       Date:  2008-04-29       Impact factor: 19.103

3.  Cyclophosphamide therapy of severe systemic necrotizing vasculitis.

Authors:  A S Fauci; P Katz; B F Haynes; S M Wolff
Journal:  N Engl J Med       Date:  1979-08-02       Impact factor: 91.245

4.  Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients.

Authors:  Mathilde de Menthon; Pascal Cohen; Christian Pagnoux; Matthias Buchler; Jean Sibilia; Frédérick Détrée; Martine Gayraud; Mehdi Khellaf; Christian Penalba; Bruno Legallicier; Luc Mouthon; Loïc Guillevin
Journal:  Clin Exp Rheumatol       Date:  2011-05-11       Impact factor: 4.473

5.  Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides.

Authors:  Guillaume Le Guenno; Alfred Mahr; Christian Pagnoux; Robin Dhote; Loïc Guillevin
Journal:  Arthritis Rheum       Date:  2011-05

6.  Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients.

Authors:  Loïc Guillevin; Pascal Cohen; Alfred Mahr; Jean-Pierre Arène; Luc Mouthon; Xavier Puéchal; Edouard Pertuiset; Brigitte Gilson; Mohamed Hamidou; Patricia Lanoux; Alain Bruet; Marc Ruivard; Philippe Vanhille; Jean-François Cordier
Journal:  Arthritis Rheum       Date:  2003-02-15

7.  Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.

Authors:  Anthony Booth; Lorraine Harper; Tariq Hammad; Paul Bacon; Megan Griffith; Jeremy Levy; Caroline Savage; Charles Pusey; David Jayne
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

8.  Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.

Authors:  Christian Pagnoux; Alfred Mahr; Mohamed A Hamidou; Jean-Jacques Boffa; Marc Ruivard; Jean-Pierre Ducroix; Xavier Kyndt; François Lifermann; Thomas Papo; Marc Lambert; José Le Noach; Mehdi Khellaf; Dominique Merrien; Xavier Puéchal; Stéphane Vinzio; Pascal Cohen; Luc Mouthon; Jean-François Cordier; Loïc Guillevin
Journal:  N Engl J Med       Date:  2008-12-25       Impact factor: 91.245

9.  Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients.

Authors:  L Guillevin; O Fain; F Lhote; B Jarrousse; D Le Thi Huong; A Bussel; A Leon
Journal:  Arthritis Rheum       Date:  1992-02

10.  Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients.

Authors:  Camillo Ribi; Pascal Cohen; Christian Pagnoux; Alfred Mahr; Jean-Pierre Arène; Dominique Lauque; Xavier Puéchal; Philippe Letellier; Philippe Delaval; Jean-François Cordier; Loïc Guillevin
Journal:  Arthritis Rheum       Date:  2008-02
View more
  3 in total

Review 1.  Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective.

Authors:  Ágnes Haris; Szilveszter Dolgos; Kálmán Polner
Journal:  Int Urol Nephrol       Date:  2016-09-26       Impact factor: 2.370

Review 2.  Endothelial Response to Glucocorticoids in Inflammatory Diseases.

Authors:  Karolina A Zielińska; Laura Van Moortel; Ghislain Opdenakker; Karolien De Bosscher; Philippe E Van den Steen
Journal:  Front Immunol       Date:  2016-12-14       Impact factor: 7.561

3.  Case report: de novo ANCA-associated vasculitis after kidney transplantation treated with rituximab and plasma exchange.

Authors:  Michael S Sagmeister; Max Weiss; Peter Eichhorn; Antje Habicht; Rupert Habersetzer; Michael Fischereder; Ulf Schönermarck
Journal:  BMC Nephrol       Date:  2018-10-19       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.